Scientific article

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

Published inBone, vol. 42, no. 5, p. 841-847
Publication date2008

A potential side effect associated with bisphosphonates, a class of drugs used in the treatment of osteoporosis, Paget's disease and metastatic bone disease, is osteonecrosis of the jaw (ONJ). The incidence of ONJ in the general population is unknown; this rare condition also may occur in patients not receiving bisphosphonates. Case reports have discussed ONJ development in patients with multiple myeloma or metastatic breast cancer receiving bisphosphonates as palliation for bone metastases. These patients are also receiving chemotherapeutic agents that might impair the immune system and affect angiogenesis. The incidence or prevalence of ONJ in patients taking bisphosphonates for osteoporosis seems to be very rare. No causative relationship has been unequivocally demonstrated between ONJ and bisphosphonate therapy. A majority of ONJ occurs after tooth extraction. Furthermore, the underlying risk of developing ONJ may be increased in osteoporotic patients by comorbid diseases. Treatment for ONJ is generally conservative.

  • Diphosphonatess/adverse effects/therapeutic use
  • Humans
  • Jaw Diseases/chemically induced/therapy
  • Osteitis Deformans/drug therapy
  • Osteonecrosis/chemically induced/therapy
  • Osteoporosis/drug therapy
  • Risk Factors
Research group
Citation (ISO format)
RIZZOLI, René et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. In: Bone, 2008, vol. 42, n° 5, p. 841–847. doi: 10.1016/j.bone.2008.01.003
Main files (1)
Article (Accepted version)
ISSN of the journal1873-2763

Technical informations

Creation02/24/2009 1:54:00 PM
First validation02/24/2009 1:54:00 PM
Update time03/14/2023 3:00:59 PM
Status update03/14/2023 3:00:58 PM
Last indexation01/15/2024 6:13:10 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack